

KELLY A. AYOTTE  
NEW HAMPSHIRE

144 RUSSELL BUILDING  
WASHINGTON, DC 20510

1200 ELM STREET, SUITE 2  
MANCHESTER, NH 03101

144 MAIN STREET  
NASHUA, NH 03060

14 MANCHESTER SQUARE, SUITE 140  
PORTSMOUTH, NH 03801

19 PLEASANT STREET, SUITE 13B  
BERLIN, NH 03570

## United States Senate

WASHINGTON, DC 20510

(202) 224-3324

August 30, 2016

COMMITTEES:  
ARMED SERVICES  
COMMERCE  
HOMELAND SECURITY &  
GOVERNMENTAL AFFAIRS  
BUDGET  
SMALL BUSINESS

The Honorable Andy Slavitt  
Acting Administrator  
Centers for Medicare & Medicaid Services  
7500 Security Boulevard  
Baltimore, MD 21244

Dear Acting Administrator Slavitt:

The EpiPen is an emergency lifeline for the millions of individuals who are at risk for severe allergic reactions, and recent news that Mylan Pharmaceuticals has raised the price of an EpiPen Two-Pack from \$100 in 2007 to nearly \$600 today is deeply troubling. While I am supportive of the Senate Judiciary Committee's efforts to get more information on this drastic increase, I write to you to respectfully request answers regarding the impact this price change has had on the government's prescription drug costs through Medicare Part D, Medicaid, and the Children's Health Insurance Program (CHIP).

In addition, Mylan Pharmaceuticals has recently announced that they will introduce a generic version of the EpiPen at a price of \$300. That action appears to have only come as a result of the recent public outcry concerning the drug's cost. However, I am concerned that there are still further questions Mylan must answer regarding why the price was so high in the first place, and whether this move will be enough to make this life-saving drug accessible to those who need it most, as well as its impact on the government's prescription drug costs.

As such, I respectfully request that you provide information regarding the impact Mylan's price changes have had on the Medicare Part D, Medicaid, and CHIP programs since the company acquired EpiPen in 2007. I look forward to your response and to working with you to ensure that there is an affordable and accessible option for individuals at risk from severe allergies.

Sincerely,



Kelly A. Ayotte  
U.S. Senator